


PRODUCT INFORMATION



SRS11-92

Item No. 25689

CAS Registry No.: 1467047-25-1
Formal Name: 4-(cyclohexylamino)-3-[(phenylmethyl)amino]-benzoic acid, ethyl ester
Synonym: AA9
MF: C₂₂H₂₈N₂O₂
FW: 352.5
Purity: ≥98%
UV/Vis.: λ_{max}: 250, 298, 323 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SRS11-92 is supplied as a crystalline solid. A stock solution may be made by dissolving the SRS11-92 in the solvent of choice. SRS11-92 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of SRS11-92 in ethanol and DMSO is approximately 10 mg/ml and approximately 30 mg/ml in DMF.

SRS11-92 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SRS11-92 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. SRS11-92 has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

SRS11-92 is a ferroptosis inhibitor and a derivative of ferrostatin-1 (Item No. 17729).¹ It inhibits ferroptotic cell death induced by erastin (Item No. 17754) in HT-1080 human fibrosarcoma cells (EC₅₀ = 6 nM). SRS11-92 (2 μM) inhibits iron-induced cell death in isolated mouse kidney proximal tubules, and fully protects rat oligodendrocytes from cystine deprivation-induced cell death in an *in vitro* model of periventricular leukomalacia when used at a concentration of 100 nM. It also increases survival of medium spiny neurons in rat corticostriatal brain slices in an *in vitro* model of Huntington's disease in a concentration-dependent manner. SRS11-92 (3 μM) increases production of reactive oxygen species (ROS) in *L. major* promastigotes in a time-dependent manner.² It is selectively toxic to *L. major* promastigotes (LD₅₀ = 3.34 μM) over U2OS human osteoblasts, RAW 264.7 macrophages, and intraperitoneal macrophages when used at a concentration of 80 μM.

References

- Skouta, R., Dixon, S.J., Wang, J., et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. *J. Am. Chem. Soc.* **136**(12), 4551-4556 (2014).
- Iniguez, E.A., Perez, A., Maldonado, R.A., et al. Novel arylalkylamine compounds exhibits potent selective antiparasitic activity against *Leishmania major*. *Bioorg. Med. Chem. Lett.* **25**(22), 5315-5320 (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/16/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM